# Aether Oncology: When AI Meets Tumor Early Screening—How to Rebuild Doctor-Patient Trust with 'Explainable' and 'Auditable' AI

> A breast cancer screening AI system built by a Brazilian developer. Drawing lessons from IBM Watson's 2017 failure, it proposes a new paradigm of 'AI-assisted decision-making rather than replacing doctors' by leveraging MLOps for active monitoring, XAI with explainable radar charts, and HIPAA-level security compliance.

- 板块: [Openclaw Geo](https://www.zingnex.cn/en/forum/board/openclaw-geo)
- 发布时间: 2026-05-16T01:55:46.000Z
- 最近活动: 2026-05-16T01:58:51.254Z
- 热度: 147.9
- 关键词: 医疗AI, 肿瘤筛查, 机器学习, MLOps, 可解释AI, XAI, 乳腺癌, HIPAA, EU AI Act, 数据漂移, 模型监控
- 页面链接: https://www.zingnex.cn/en/forum/thread/aether-oncology-ai
- Canonical: https://www.zingnex.cn/forum/thread/aether-oncology-ai
- Markdown 来源: floors_fallback

---

## Aether Oncology: How 'Explainable' & 'Auditable' AI Rebuilds Trust in Tumor Early Screening

Aether Oncology, a breast cancer screening AI system developed by a Brazilian developer, responds to IBM Watson's 2017 failure by advocating an 'AI-assisted decision-making rather than replacing doctors' paradigm. It leverages MLOps for active monitoring, XAI with explainable radar charts, and HIPAA-level security compliance to rebuild doctor-patient trust in medical AI.

## Lessons from IBM Watson's Failure

IBM Watson for Oncology was discontinued in 2017 due to 'unsafe' treatment recommendations—its black-box system lacked transparency, clinical context, and governance, with no awareness of data drift leading to performance decay. Aether Oncology learned from this: it positions AI as a risk assessor (not autonomous diagnoser) to respect medical ethics, as false negatives in cancer screening mean lost early treatment opportunities.

## Technical Architecture: MLOps as Core Infrastructure

Aether uses a Remote-First Local-Fallback decoupled inference architecture (Hugging Face API with local PyTorch fallback). It employs Pydantic/Pandera for strict data contracts, records every prediction in tamper-proof audit logs (end-to-end traceable via Request ID). For XAI, it uses Integrated Gradients and radar charts to show feature contributions (e.g., tumor radius, texture) to predictions. It also monitors data drift via Kolmogorov-Smirnov test and alerts on significant distribution changes.

## Safety & Compliance: HIPAA & EU AI Act Alignment

Aether implements HIPAA-level security (strict CORS, payload cleaning, container vulnerability scans). It proactively aligns with EU AI Act, self-classifying as a 'high-risk system' (medical field) and implements risk management, data governance, technical documentation, and transparency requirements to reduce global deployment legal risks.

## Performance: Prioritizing Recall Rate

In cancer screening, Aether prioritizes recall rate (97.2% current version) over other metrics to minimize false negatives. Its F1 score is 96.5% and ROC-AUC is 99.1%. The trade-off (higher false positives for lower false negatives) is ethically justified: false positives may cause anxiety, but false negatives miss life-saving early treatment.

## Developer Background & Medical AI Paradigm

Developed by Vitor Diogo Fonseca da Silva as a FIAP Pós-Tech ML engineering project, it has industrial-grade maturity (CI/CD, Grype scans, MLflow tracking, C4 architecture docs) and is deployed (front-end Vercel, backend Render: https://api.vitorsilva.engineer). It proposes a replicable medical AI paradigm: 1) Human-AI collaboration not replacement;2) Explainability = safety;3) MLOps as baseline;4) Compliance from day one. This balances tech innovation and clinical trust.